Herve Hoppenot
Special Advisor to the CEO at Incyte Corp.
Sits on 3 boards. Last updated September 27, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 3 boards, counting each seat separately. Longest: Incyte Corp., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Incyte Corp. June 10, 202594.2%
-
Incyte Corp. June 12, 202493.1%
-
Incyte Corp. June 14, 202393.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 2, 2026 | Bicycle Therapeutics plc | Grant or award | +3,032 | — | — |
| Dec 8, 2025 | Incyte Corp. | Shares withheld for tax | −2,843 | $96.70 | $274,918 |
| Nov 10, 2025 | Incyte Corp. | Open-market sale | −187,500 | $105.46 | $19,773,750 |
| Sep 8, 2025 | Bicycle Therapeutics plc | Grant or award | +12,500 | — | — |
| Jul 15, 2025 | Incyte Corp. | Shares withheld for tax | −4,713 | $68.25 | $321,662 |
| Jul 14, 2025 | Incyte Corp. | Shares withheld for tax | −4,961 | $69.98 | $347,171 |
| Jul 2, 2025 | Incyte Corp. | Shares withheld for tax | −42,769 | $68.17 | $2,915,563 |
| Jun 26, 2025 | Incyte Corp. | Grant or award | +6,016 | — | — |
| Apr 1, 2025 | Incyte Corp. | Grant or award | +66,899 | — | — |
| Jul 15, 2024 | Incyte Corp. | Grant or award | +41,025 | — | — |
| Jul 15, 2024 | Incyte Corp. | Shares withheld for tax | −4,961 | $64.25 | $318,744 |
| Jul 2, 2024 | Incyte Corp. | Shares withheld for tax | −41,723 | $59.02 | $2,462,491 |
| Feb 14, 2024 | Incyte Corp. | Grant or award | +41,577 | — | — |
| Jul 14, 2023 | Incyte Corp. | Grant or award | +43,184 | — | — |
| Jul 3, 2023 | Incyte Corp. | Shares withheld for tax | −43,467 | $62.08 | $2,698,431 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.